Review





Similar Products

ras g lisa activation assay kit  (Cytoskeleton Inc)
95
Cytoskeleton Inc ras g lisa activation assay kit
Ras G Lisa Activation Assay Kit, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/Ras+G-LISA+GTPase+Activation+Assay+Kit/pmc13049409-257-6-11
Average 95 stars, based on 1 article reviews
ras g lisa activation assay kit - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
rheumatoid arthritis (ra) registry  (Corrona LLC)
90
Corrona LLC rheumatoid arthritis (ra) registry
Rheumatoid Arthritis (Ra) Registry, supplied by Corrona LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/rheumatoid+arthritis+registry/nct02707341-0-9-8
Average 90 stars, based on 1 article reviews
rheumatoid arthritis (ra) registry - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
retinoic acid ra mce cat hy 14649  (MedChemExpress)
95
MedChemExpress retinoic acid ra mce cat hy 14649
Retinoic Acid Ra Mce Cat Hy 14649, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/Retinoic+acid/pm42585016-166-116-119
Average 95 stars, based on 1 article reviews
retinoic acid ra mce cat hy 14649 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
ra receptor rars antagonists agn 193109  (MedChemExpress)
94
MedChemExpress ra receptor rars antagonists agn 193109
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Ra Receptor Rars Antagonists Agn 193109, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/AGN+193109/pmc13298773-230-19-25
Average 94 stars, based on 1 article reviews
ra receptor rars antagonists agn 193109 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
rapamycin ra  (Thermo Fisher)
95
Thermo Fisher rapamycin ra
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Rapamycin Ra, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/Rapamycin%2C+98%2B%25/pm42340987-43-0-5
Average 95 stars, based on 1 article reviews
rapamycin ra - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
heat inactivated m tuberculosis h37 ra  (Difco)
86
Difco heat inactivated m tuberculosis h37 ra
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Heat Inactivated M Tuberculosis H37 Ra, supplied by Difco, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/h37ra+mycobacterium+tuberculosis/pmc08590855-35-38-44
Average 86 stars, based on 1 article reviews
heat inactivated m tuberculosis h37 ra - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
ramos b cell lysate ramos ra 1 b cells  (ATCC)
99
ATCC ramos b cell lysate ramos ra 1 b cells
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Ramos B Cell Lysate Ramos Ra 1 B Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/Ramos/us12656342-490-5-13
Average 99 stars, based on 1 article reviews
ramos b cell lysate ramos ra 1 b cells - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
il ra  (Measurand Inc)
86
Measurand Inc il ra
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Il Ra, supplied by Measurand Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/il+ra/pm42295141-336-16-14
Average 86 stars, based on 1 article reviews
il ra - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
rapamycin ra  (MedChemExpress)
98
MedChemExpress rapamycin ra
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Rapamycin Ra, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/Rapamycin/pm42262972-143-15-17
Average 98 stars, based on 1 article reviews
rapamycin ra - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
image based ra tka  (Stryker)
86
Stryker image based ra tka
(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist <t>AGN</t> <t>193109</t> (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .
Image Based Ra Tka, supplied by Stryker, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ras/based+image/pm42257756-3-11-14
Average 86 stars, based on 1 article reviews
image based ra tka - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


(A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist AGN 193109 (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .

Journal: PLOS Biology

Article Title: Angptl5 restricts primitive hematopoiesis by promoting retinoic acid signaling in zebrafish

doi: 10.1371/journal.pbio.3003858

Figure Lengend Snippet: (A) WISH of cyp26a1 in WT embryos. Embryos were treated with ERK activator (C16-PAF, ERKa) or ERK inhibitor (Mirdametinib, ERKi) from the shield stage, or injected with angptl5 + itga6l + itgb5 mRNA at the 1-cell stage. Untreated embryos were used as control. (B–D) Schematic diagram of experimental setup (B) for WISH of dhrs9 and aldh1a2 in WT embryos. caERK2 (C) or angptl5 + itga6l + itgb5 (D) mRNA injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (E–G) Schematic diagram of experimental setup (E) for WISH of dhrs9 . WT embryos were first injected with angptl5 mRNA at the 1-cell stage. Subsequently, itga6l ± itgb5 mRNA was injected into one blastomere on the animal pole at the 128-cell stage. Embryos were then continuously treated with or without ERK inhibitor until the shield stage (G) . Uninjected embryos and only angptl5 mRNA injected embryos (F) were used as control. (H) WISH of dhrs9 in WT embryos. caERK2 mRNA ± junba/bb MO injected into one blastomere on the animal pole at the 128-cell stage and then detected at 6 hpf. (I) ChIP-qPCR analysis of Junb binding to upstream regions of dhrs9. Embryos injected with HA-Junba mRNA were subjected to chromatin immunoprecipitation with HA-agarose, using IgG-agarose as a control. Enrichment at three predicted binding sites upstream of the dhrs9 gene was quantified by qPCR. Data are presented as the mean ± SD from three independent biological replicates. *** P < 0.001 (Unpaired t t est). (J and K) WISH of spi1b in angptl5 Δ10/Δ10 embryos. Embryos were injected with itga6l + itgb5 mRNA at the 1-cell stage and treated with or without ERK inhibitor from the shield stage to the 18-somite stage (J), or injected with caERK 2 mRNA at the 1-cell stage and treated with or without RA receptor antagonist AGN 193109 (K). Uninjected embryos were used as control. Statistics are shown below. Data presented as the mean ± SD, n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + itga6l + itgb5 ) = 26, n( angptl5 Δ10/Δ10 + itga6l + itgb5 + ERKi) = 28 (J); n( angptl5 Δ10/Δ10 ) = 22, n( angptl5 Δ10/Δ10 + caERK ) = 22, and n( angptl5 Δ10/Δ10 + caERKi + AGN) = 26 (K). Statistical significance: ** P < 0.01, *** P < 0.001 (One-way ANOVA). LV, lateral view; AV, animal view (C–H), anterior view (J and K). The data for this figure can be found in .

Article Snippet: Detailed pharmacological parameters and experimental concentrations are tabulated below: RA (sigma), Aldehyde dehydrogenase inhibitors 4-diethylaminobenzaldehyde (DEAB) (MCE, 10 μM), RA receptor (RARs) antagonists AGN 193109 (MCE, 20 μM), FAK inhibitor Defactinib (MCE, 2 μM/8 μM), MAPK inhibitor Adezmapimod (MCE, 10 μM), ERK inhibitor Mirdametinib (MCE, 10 μM), ERK activator C16-PAF (MCE, 1 μM/5 μM), NF-κB inhibitor BAY 11-7082 (MCE, 0.1 μg/mL, 0.4 μg/mL).

Techniques: Injection, Control, ChIP-qPCR, Binding Assay, Chromatin Immunoprecipitation